Method for identifying high-risk AML patients
US11111542B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Feb 6, 2017 |
| Grant date | Sep 7, 2021 |
| Priority date | — |
| Expiry date | Feb 6, 2037 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/60
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
There is described herein a method of prognosing or classifying a subject with acute myeloid leukemia (AML) comprising: (a) determining the expression level of at least 3 genes in a test sample from the subject selected from the group consisting of DNMT3B, ZBTB46, NYNRIN, ARHGAP22, LAPTM4B, MMRN1, DPYSL3, KIAAQ125. CDK6, CPXM1, SOCS2, SMIM24, EMP1, NGFRAP1, CD34, AKR1C3, GPR56; and (b) comparing expression of the at least 3 genes in the test sample with reference expression levels of the at least 3 genes from control samples from a cohort of patients; wherein a difference or similarity in the expression of the at least 3 genes in the test sample and the reference expression levels is used to prognose or classify the subject with AML into a low risk group or a high risk group for worse survival.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.